The pharma industry has warned that the UK’s stockpiles of medical supplies intended to cover disruption caused by Brexit have been “used up entirely” by the effort against the coronavirus,
The EMA has said it will fast-track the review of Gilead Sciences’ remdesivir as a treatment for COVID-19, after the US biopharma submitted its marketing application for the dr
COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.
